Anti cd38 monoclonal antibody drugs

Antineoplastic, Anti-CD38 antibody Multiple myeloma [DS:H ] Monoclonal antibody CD38 [HSA:952] [KO:K ] hsa , Hematopoietic cell lineage

Anti-CD38 monoclonal antibody may block the CD38 protein and help the immune system kill cancer cells.

These anti-CD38 monoclonal antibodies will be blockbuster drugs and an important component of multiple myeloma treatment.

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1) Immunology/Inflammation Antibody-drug

An anti-CD38 monoclonal antibody like daratumumab (Darzalex). This targets a protein on the surface of myeloma cells called CD38. A

These anti-CD38 monoclonal antibodies will be blockbuster drugs and an important component of multiple myeloma treatment.

Monoclonal antibodies are a cornerstone in the treatment of multiple myeloma. Among the available anti-CD38 monoclonal antibodies, daratumumab has been approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), while isatuximab, MOR202, and TAK-079 are currently under investigation. Anti-CD38 monoclonal antibodies have several mechanisms of action

coupling ricin to mouse anti-human CD38 monoclonal antibody HB7, the antibody-drug conjugate exhibited stronger activity killing positive

CD38 monoclonal antibodies target the CD38 surface antigen of hematopoietic cells, which is important for cell function. Once CD38 monoclonal antibodies bind to the antigen it inhibits tumour growth by interrupting CD38 functions and causes cell death. CD38 monoclonal antibodies are used to treat multiple myeloma.